Field study on the safety and efficacy of intradermal versus intramuscular vaccination against <i>Mycoplasma hyopneumoniae</i>

Beffort, Lisa; Weiß, Christine; Fiebig, Kerstin; Jolie, Rika; Ritzmann, Mathias; Eddicks, Matthias

doi:10.1136/vr.104466

Cited by 12 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the ISR occasionally observed in all IM vaccinated groups and at the IM injection site of group Lipo_DDA:TDB were mild and resolved quickly. Transient redness and swelling at vaccination sites were also reported in other M. hyopneumoniae vaccination studies (53–55). Such local reactions often occur after parenteral administration of adjuvanted vaccines and are tolerated in terms of safety (52).…”

Section: Discussionsupporting

confidence: 77%

Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins

et al. 2019

View full text Add to dashboard Cite

We characterized five different vaccine candidates and a commercial vaccine in terms of safety, immunogenicity and using a systems vaccinology approach, with the aim to select novel vaccine candidates against Mycoplasma hyopneumoniae . Seven groups of six M. hyopneumoniae -free piglets were primo- and booster vaccinated with the different experimental bacterin formulations, the commercial vaccine Hyogen® as a positive control or PBS as a negative control. The experimental bacterin was formulated with cationic liposomes + c-di-AMP (Lipo_AMP), cationic liposomes + Toll-like receptor (TLR) 2/1, TLR7, and TLR9 ligands (TLR ligands; Lipo_TLR), micro-particles + TLR ligands (PLGA_TLR), squalene-in-water emulsion + TLR ligands (SWE_TLR), or DDA:TDB liposomes (Lipo_DDA:TDB). Lipo_DDA:TDB and Lipo_AMP were the most potent in terms of serum antibody induction, and Lipo_DDA:TDB, Lipo_AMP, and SWE_TLR significantly induced Th1 cytokine-secreting T-cells. Only PLGA_TLR appeared to induce Th17 cells, but was unable to induce serum antibodies. The transcriptomic analyses demonstrated that the induction of inflammatory and myeloid cell blood transcriptional modules (BTM) in the first 24 h after vaccination correlated well with serum antibodies, while negative correlations with the same modules were found 7 days post-vaccination. Furthermore, many cell cycle and T-cell BTM upregulated at day seven correlated positively with adaptive immune responses. When comparing the delivery of the identical TLR ligands with the three formulations, we found SWE_TLR to be more potent in the induction of an early innate immune response, while the liposomal formulation more strongly promoted late cell cycle and T-cell BTM. For the PLGA formulation we found signs of a delayed and weak perturbation of these BTM. Lipo_AMP was found to be the most potent vaccine at inducing a BTM profile similar to that correlating with adaptive immune response in this and other studies. Taken together, we identified four promising vaccine candidates able to induce M. hyopneumoniae -specific antibody and T-cell responses. In addition, we have adapted a systems vaccinology approach developed for human to pigs and demonstrated its capacity in identifying early immune signatures in the blood relating to adaptive immune responses. This approach represents an important step in a more rational design of efficacious vaccines for pigs.

show abstract

Section: Discussionsupporting

confidence: 77%

Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Many other researchers found that Mhp commercial vaccines are not effective in mouse immunization experiments [9,10,26,27,28]. However, similar commercial vaccines have been proved to be safe and effective in experimental or field conditions of piglet immunization [7,29,30,31]. The types of vaccines used in these studies are inactivated or attenuated vaccines, which is similar to the inactivated Mhp vaccine used in this study, while the PCV2 vaccine used in this study is a protein-type vaccine, so it works well in both mouse and pig experiments.…”

Section: Discussionmentioning

confidence: 99%

Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System

Zheng

et al. 2019

IJMS

View full text Add to dashboard Cite

Mycoplasma hyopneumoniae (Mhp) and porcine circovirus type 2 (PCV2) are the main pathogens for mycoplasmal pneumonia of swine (MPS) and post-weaning multisystemic wasting syndrome (PMWS), respectively. Infection by these pathogens often happens together and causes great economic losses. In this study, a kind of recombinant baculovirus that can display P97R1P46P42 chimeric protein of Mhp and the capsid (Cap) protein of PCV2 was developed, and the protein location was identified. Another recombinant baculovirus was constructed without tag proteins (EGFP, mCherry) and was used to evaluate the immune effect in experiments with BALB/c mice and domestic piglets. Antigen proteins P97R1P46P42 and Cap were expressed successfully; both were anchored on the plasma membrane of cells and the viral envelope. It should be emphasized that in piglet immunization, the recombinant baculovirus vaccine achieved similar immunological effects as the mixed commercial vaccine. Both the piglet and mouse experiments showed that the recombinant baculovirus was able to induce humoral and cellular responses effectively. The results of this study indicate that this recombinant baculovirus is a potential candidate for the further development of more effective combined genetic engineering vaccines against MPS and PMWS. This experiment also provides ideas for vaccine development for other concomitant diseases using the baculovirus expression system.

show abstract

“…Within the wide range of vaccine products available, all of them are for intramuscular administration, except one vaccine for intradermal application. Studies by Martelli et al, [12], Tassis et al, [13], and Beffort et al, [14] have demonstrated, not only the greater e cacy of this product against other vaccines for intramuscular use (in terms of average daily weight gain (ADWG), reduction of clinical signs and lung lesions) but also an increase in the levels of local protection at the pulmonary level with respect to some vaccines, measured in the form of IgA and levels of Il-10.…”

Section: Introductionmentioning

confidence: 95%

Field Trial Assessment of Two Commercial Vaccines Against Mycoplasma Hyopneumoniae

Marcos¹,

Rabanal²,

Pico³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Mycoplasma hyopneumoniae (M.hyo) is one of the most prevalent pathogens causing respiratory disorders in swine populations as well as primary agent of porcine respiratory disease complex (PRDC). The aim of this trial is to compare the efficacy of two commercial vaccines under field conditions, applied via different routes of administration, as a tool to control disease.Results: 3 groups each consisting of 440 animals, were included in this longitudinal study; one group vaccinated against M.hyo with an intradermal vaccine (group I), a second group vaccinated with an intramuscular vaccine 2940 strain (group H) and finally a third group, not vaccinated as a control (group N). All animals were individually weighed at weaning; upon entry into the fattening unit and just prior to movement to the slaughterhouse. Pigs from each group were periodically blood sampled to evaluate the immunological status against other pathogens involved in PRDC. Tracheobronchial swabs were collected from 30 pigs per treatment group during the final weighing. Slaughterhouse lung lesion evaluations were developed to assess levels of enzootic pneumonia-like lesions (EP) and pleuritis (P).Statistical evaluation of all test parameters indicated a better performance of the intradermal vaccinated group (group I):· in terms of weight (kg) just prior to movement to the slaughterhouse, (I= 97.45; H = 93.44; N = 93.05).· The number of positive tracheobronchial swabs, as well as M.hyo load detected individually (I = 36.7% positive samples with log10 Ct average value 1.48; H = 100% with log10 Ct 1.40; and N = 96.7% with log10 Ct 1.40),· EP prevalence (I = 35.1%, H = 47.0%, N = 50.5%) and· Pleurisy prevalence (I = 22.4%, H = 29.7%, N = 39.3%).In terms of the involvement of other PRDC pathogens, the serological study could lead us to think that the agents studied were present at same level in the all 3 vaccination groups.Conclusion: In this study, intradermal vaccination provided better performance than unvaccinated control group and intramuscular vaccine, in terms of weight increase (versus intramuscular group); reduction of enzootic pneumonia and pleurisy lesions, and tracheobronchial M.hyo prevalence at the end of the finishing period.

show abstract

Field study on the safety and efficacy of intradermal versus intramuscular vaccination against Mycoplasma hyopneumoniae

Cited by 12 publications

References 31 publications

Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins

Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins

Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System

Field Trial Assessment of Two Commercial Vaccines Against Mycoplasma Hyopneumoniae

Contact Info

Product

Resources

About